Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Leuven – page 51

1 129 clinical trials in Leuven, Belgium across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Leuven at a glance
1 129
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 129 trials in Leuven

Open in trial search

Prostate cancer metastatic

Not recruiting

Effect of a high‑fat meal on MK‑5684, fludrocortisone and prednisone pharmacokinetics and hormone levels in healthy men relevant to refractory metastatic prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Fludrocortisone
  • Sponsor:Merck Sharp & Dohme LLC

Osteoarthritis

Not recruiting

Safety, tolerability and pharmacokinetics of intra‑articular 4P‑004 versus sodium chloride placebo in patients with knee osteoarthritis (grade 2‑4)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Liraglutide
  • Sponsor:4moving Biotech

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Pain

Not recruiting

Safety, Tolerability and Pharmacokinetics of MK-4318 in Healthy Adults with Pain

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Merck Sharp & Dohme LLC

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib
  • Sponsor:Ipsen Innovation

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib
  • Sponsor:Merck Healthcare KGaA

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Chronic obstructive pulmonary disease

Not recruiting

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Dermatomyositis

Not recruiting

A study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Pulmonary arterial hypertension

Not recruiting

A Study of PF-07868489 Safety and Effectiveness in Adults with Pulmonary Arterial Hypertension Who Participated in a Previous PF-07868489 Trial

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:PF-07868489
  • Sponsor:Pfizer Inc.

Pulmonary arterial hypertension

Not recruiting

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Leuven

What the registry says about research in the country

01 Gastrointestinal Research

Clinical investigations focusing on ulcerative colitis and innovative treatments for inflammatory bowel conditions. Studies include evaluation of novel therapies for short bowel syndrome and gastrointestinal motility disorders.

  • Inflammatory Bowel Disease Treatment
  • Gastrointestinal Motility Studies
  • Metabolic Disease Research

Current trials are examining drug absorption and therapeutic responses in patients with various digestive conditions.

02 Oncology Studies

Groundbreaking research in head and neck cancer treatments, including innovative radiotherapy approaches. Studies are also investigating new therapies for bladder cancer, focusing on early-stage interventions.

  • Advanced Cancer Therapies
  • Immunotherapy Research
  • Non-invasive Treatment Approaches

Emphasis on combining traditional treatments with novel therapeutic approaches to improve patient outcomes.

03 Neurological Disorders

Comprehensive studies on Alzheimer's disease and frontotemporal dementia, investigating disease progression and potential treatments. Research includes innovative approaches to understanding brain circuit functionality.

  • Cognitive Function Studies
  • Neurodegenerative Disease Research
  • Brain Imaging Technologies

Advanced imaging techniques are being utilized to track disease progression and treatment effectiveness.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.